$0.95
+0.15 (+19.22%)
Open$0.80
Previous Close$0.79
Day High$0.95
Day Low$0.80
52W High$15.00
52W Low$0.73
Volume—
Avg Volume159.8K
Market Cap4.30M
P/E Ratio—
EPS$-5.21
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,035.7% upside
Current
$0.95
$0.95
Target
$20.24
$20.24
$14.74
$20.24 avg
$23.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.23M | 4.47M | 3.50M |
| Net Income | -124,680 | -125,666 | -103,892 |
| Profit Margin | -3.0% | -2.8% | -3.0% |
| EBITDA | -157,557 | -149,483 | -127,277 |
| Free Cash Flow | -89,797 | -95,523 | -91,369 |
| Rev Growth | +15.0% | +2.0% | +12.9% |
| Debt/Equity | 1.05 | 1.12 | 1.09 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |